DataString Consulting Company Logo
DataString Consulting Company Logo
Plecanatide Market
Home»Recent Reports»Plecanatide Market

Plecanatide Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802132, Published - March 2025

Segmented in Therapeutic Application (Chronic Idiopathic Constipation, Irritable Bowel Syndrome), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Dosage Formulation, Prescription Mode, Patient Demographics and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Plecanatide Market Outlook

The market, for Plecanatide was estimated at $478.0 million in 2024; and it is anticipated to increase to $674.2 million by 2030 with projections indicating a growth to around $898.0 million by 2035. This expansion represents a compound annual growth rate (CAGR) of 5.9% over the forecast period. Plecanatides impressive growth can be attributed to key factors that have enhanced its market significance over time. The dedication to innovation and the advancements in gastrointestinal medication technology have played a role in shaping its success story. The pharmaceuticalindustry'srising demands also contribute significantly to Plecanatides future outlook. Through advancements and well planned product launches Plecanatide has gained traction in the market and is poised to maintain its competitive edge, for the foreseeable future. Impressive enhancements in results and the recent approvals, for new applications have contributed to the growth of the market.


Plecanatide is considered a medication in the field of pharmaceuticals and plays a crucial role in managing chronic idiopathic constipation (CID) and irritable bowel syndrome with constipation (IBS C). Developed using peptide technology it functions by boosting fluid levels in the intestines to promote regular bowel movements and has a significant impact on improving the quality of life for patients. Keeping pace with evolving trends, in the pharmaceutical industry Plecanatide has emerged as an well received treatment option that is meeting increasing demand.


Market Size Forecast & Key Insights

2019
$477M2024
2029
$847M2034

Absolute Growth Opportunity = $370M

The Plecanatide market is projected to grow from $478.0 million in 2024 to $847 million in 2034. This represents a CAGR of 5.9%, reflecting rising demand across Chronic Idiopathic Constipation Treatment, Gastrointestinal Function Regulation and Irritable Bowel Syndrome Management.

The Plecanatide market is set to add $370 million between 2024 and 2034, with manufacturer targeting Retail Pharmacies & Online Pharmacies Distribution Channel projected to gain a larger market share.

With Rising prevalence of chronic idiopathic constipation , and Aging global population, Plecanatide market to expand 77% between 2024 and 2034.

Opportunities in the Plecanatide Market

Strategic Collaborations for Market Expansion

To expand the reach of Plecanatide effectively and efficiently worldwide in regions facing rates of gastrointestinal disorders​, strategic partnerships and collaborations, with research institutes, healthcare companies and pharmaceutical firms can play a pivotal role.

Exploring Untapped Therapeutic Segments and Harnessing Technological Innovations

The market is seeing a growing need for faster medical solutions lately that hasnt been fully explored yet by Plecanatide as they venture into treating gastrointestinal issues more effectively This trend, towards personalized healthcare and specific treatments will make the most of Plecanatides special qualities.

Plecanatide, known for its application in treating chronic idiopathic constipation, has a lucrative future in the advent of technology. Technological innovations offer immense possibilities for Plecanatide in terms of drug delivery systems, optimization of drug design, and precision medicine.

Growth Opportunities in North America and Europe

Europe Outlook

In Europe compared to North America Plecanatide displays a market scenario. The UK, Germany and France stand out in the region for their consumption and demand levels. The increasing elderly population in these nations who are particularly prone to issues such as CIC and IBS C plays a pivotal role in driving the growth of Plecanatide. The drugs effectiveness and safety features have contributed to its use, in this region.

North America Outlook

In North America's territory Plecanatide has firmly established itself notably within the United States due to the rising cases of chronic idiopathic constipation and irritable bowel syndrome with constipation . The sectors extensive research and development efforts in the region provide numerous prospects for Plecanatide to thrive. There is a focus on enhancing patient comfort and convenience along with effective strategic marketing and promotional campaigns, by major industry players that contribute to its success. Nevertheless competition from therapeutic medications such as Linaclotide and Lubiprostone presents hurdles in the market adoption of Plecanatide. The increased interest in drug research among specialists and the rise in sedentary lifestyles contributing to a higher prevalence of constipation related conditions further complicate matters. It is important to consider the per capita healthcare spending indicating market potential, for Plecanatide.

North America Outlook

In North America's territory Plecanatide has firmly established itself notably within the United States due to the rising cases of chronic idiopathic constipation and irritable bowel syndrome with constipation . The sectors extensive research and development efforts in the region provide numerous prospects for Plecanatide to thrive. There is a focus on enhancing patient comfort and convenience along with effective strategic marketing and promotional campaigns, by major industry players that contribute to its success. Nevertheless competition from therapeutic medications such as Linaclotide and Lubiprostone presents hurdles in the market adoption of Plecanatide. The increased interest in drug research among specialists and the rise in sedentary lifestyles contributing to a higher prevalence of constipation related conditions further complicate matters. It is important to consider the per capita healthcare spending indicating market potential, for Plecanatide.

Europe Outlook

In Europe compared to North America Plecanatide displays a market scenario. The UK, Germany and France stand out in the region for their consumption and demand levels. The increasing elderly population in these nations who are particularly prone to issues such as CIC and IBS C plays a pivotal role in driving the growth of Plecanatide. The drugs effectiveness and safety features have contributed to its use, in this region.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : United States, Germany, United Kingdom, Japan, Canada are expected to grow at 3.8% to 5.7% CAGR

2

Emerging Markets : Brazil, South Africa, Indonesia are expected to grow at 6.8% to 8.1% CAGR

Market Analysis Chart

The changing market for Plecanatide is shaped by key factors that offer both opportunities and obstacles for its future development. The demand for medications to treat chronic idiopathic constipation is a major driving force behind the growth of the Plecanatide market. With its recognized effectiveness and safety profile Plecanatide plays a role, in gastrointestinal treatment options and is opening up new pathways in the field of pharmaceuticals.

Recent Developments and Technological Advancement

December 2024

Pfizer has expanded its range of Plecanatide products by introducing an improved version specifically designed for patients suffering from Irritable Bowel Syndrome showing positive outcomes, in various clinical studies.

October 2024

Allergan went ahead with a phase ‒ three clinical trial for their Plecanatide product to gain deeper insights, into how the medication affects the digestive system of humans.

June 2024

Synergy Pharmaceuticals collaborated with Johnson & Johnson to further develop next generation Plecanatide medications.

there have been advancements in the pharmaceutical industry regarding Plecanatide treatment for chronic idiopathic constipation and irritable bowel syndrome with constipation . Known as Trulance, in the field this treatment has become popular for its effectiveness and patient friendly nature.

Impact of Industry Transitions on the Plecanatide Market

As a core segment of the Pharmaceutical industry, the Plecanatide market develops in line with broader industry shifts. Over recent years, transitions such as Emergence of Personalized Medicine and Digitalization in the Pharmaceutical Industry have redefined priorities across the Pharmaceutical sector, influencing how the Plecanatide market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Emergence of Personalized Medicine:

The healthcare sector is undergoing a transformation with personalized medicine leading the way especially in gastroenterology where Plecanatide plays a key role in treatment strategies. Embracing treatment methods holds promise for improving patient well being by customizing therapies to suit each individuals specific requirements. This shift towards personalization influences the development of Plecanatide as it requires research and innovation to meet the growing need for tailored and efficient treatments, for gastrointestinal conditions.

2

Digitalization in the Pharmaceutical Industry:

The pharmaceuticalindustry'smove towards digitalization is a shift for Plecanatide to adapt to the changing landscape of healthcare technology like telemedicine and AI playing a crucial role in transforming how treatments are delivered and managed across all sectors of the industry. This shift impacts Plecanatide by opening up opportunities for patient consultations and follow up care through digital platforms that offer real time monitoring of treatment effectiveness and side effects. Such innovative approaches not only enhance communication, between patients and doctors but also hold the potential to improve treatment outcomes for individuals receiving Plecanatide prescriptions.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Plecanatide market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Rising Prevalence of Chronic Idiopathic Constipation , and Increasing Adoption of Western Diet

The rising number of people experiencing Chronic Idiopathic Constipation plays an important role in driving the market for Plecanatide. An analog polypeptide used to treat this condition. As it is also anticipated to see consistent demand with this increase, in prevalence. The medication targets the cyclase C receptors found in the intestines to improve bowel regularity and alleviate the symptoms of CID.
The rising trend towards consuming processed foods and leading a lifestyle commonly seen in Western diets has also been associated with an uptick in health issues like chronic idiopathic constipation and irritable bowel syndrome, with constipation .
The rise in the number of individuals worldwide and the corresponding uptick in gastrointestinal issues like CIC and irritable bowel syndrome with constipation are also contributing to the expansion of the Plecanatide markets scope. Plecanatide is also proving to be advantageous, for managing bowel disorders among individuals through its ability to alleviate symptoms and enhance bowel function effectively.

Restraint: Intense Competition in the Pharmaceutical Industry

The primary challenge for Plecanatide lies in the competitive landscape of the pharmaceutical sector where numerous established firms are always pushing boundaries for new advancements in treatment options and therapies. The widespread use and favoritism towards Plecanatide could encounter obstacles due to the presence of existing medications and rival products that provide comparable therapeutic advantages; thereby creating a substantial impact on market trends and the necessity for Plecanatide. Ultimately achieving success will hinge not only on the drugs efficacy but also, on the strategic promotional strategies employed to enhance its market presence and appeal to consumers.

Challenge: Regulatory Challenges and Adherence to Compliance

Navigating the regulatory environment poses another significant hurdle for Plecanatides development journey. The drugs potential may face obstacles due to regulations requisite compliances and the unpredictable nature of healthcare policies. For example the lengthy and costly processes involved in obtaining drug approvals, research trials and monitoring its performance post launch could potentially hinder its market expansion. Strategic foresight and an in depth grasp of market trends are essential to secure long term growth, in the industry.

Supply Chain Landscape

Raw Material Acquisition

Pfizer Inc

Novartis AG

API Production

GlaxoSmithKline plc

Eli Lilly and Co

Dosage Form Development
Forest Laboratories / Allergan Inc
Distribution & End-User
McKesson Corporation / AmerisourceBergen Corporation
Raw Material Acquisition

Pfizer Inc

Novartis AG

API Production

GlaxoSmithKline plc

Eli Lilly and Co

Dosage Form Development

Forest Laboratories

Allergan Inc

Distribution & End-User

McKesson Corporation

AmerisourceBergen Corporation

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Chronic Idiopathic Constipation (CIC)
Pharmaceuticals
Synergy Pharmaceuticals
Focusing on consumer awareness and education about CIC and the benefits of Plecanatide
Irritable Bowel Syndrome with Constipation (IBS-C)
Healthcare
Ironwood Pharmaceuticals
Targeting specialized healthcare providers and making a comprehensive patient support program available
Laxative Supplementations
Pharmaceuticals
Salix Pharmaceuticals
Leveraging fever marketing and retail partnerships to expand availability and accessibility of Plecanatide-based treatments

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Plecanatide market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Plecanatide in Irritable Bowel Syndrome Management and Gastrointestinal Function Regulation and Chronic Idiopathic Constipation Treatment

Irritable Bowel Syndrome Management and Gastrointestinal Function Regulation

Our investigation also highlights the importance of using Plecanatide in treating bowel syndrome . In particular Plecanatides sensitivity to pH makes it a popular choice because of its ability to regulate bowel function manage discomfort and improve the overall quality of life for those diagnosed with the condition. The drugs effectiveness is attributed to its impact and its success in alleviating IBS related stomach pain. Leading pharmaceutical company Ironwood Pharmaceuticals has embraced Plecanatide as a player in the market, for treating IBS.

Plecanatide is integral in regulating gastrointestinal function, especially in managing gastrointestinal transit time. The molecule acts by mimicking the natural activity of uroguanylin, hence promoting the balance between electrolyte and fluid absorption and secretion.

Chronic Idiopathic Constipation Treatment

Based on our findings from the study we conducted on the topic of idiopathic constipation Plecanatide. A designed version of uroguanylin. Is commonly utilized for its treatment purposes in this medical condition field. One key aspect of Plecanatides functionality lies in its ability to trigger secretion within the intestinal tract which subsequently facilitates smoother bowel movements for individuals suffering from CIC. A distinguishing feature of Plecanatide is its effectiveness in managing CIC while causing adverse reactions compared to other treatments available, in the market. Synergy Pharmaceuticals has played a role in advancing the treatment of CIC, with Plecanatide. This highlights their presence in the market.

Plecanatide vs. Substitutes:
Performance and Positioning Analysis

Plecanatide, predominantly used in gastrointestinal treatment, outshines alternatives due to its efficiency and reduced side effects, with notable market growth potential in the pharmaceutical sector. These Alternatives specially Linaclotide has experienced a rapid growth as detailed in our latest report.

Plecanatide
  • Linaclotide /
  • Lubiprostone /
  • Prucalopride
    Effective in treating chronic idiopathic constipation, minimal side effects
    Limited to adult use, possibility of severe diarrhea
    Effective in treating severe chronic idiopathic constipation, more affordable
    High risk of developing severe diarrhea, long term effects yet to be extensively studied

Plecanatide vs. Substitutes:
Performance and Positioning Analysis

Plecanatide

  • Effective in treating chronic idiopathic constipation, minimal side effects
  • Limited to adult use, possibility of severe diarrhea

Linaclotide / Lubiprostone / Prucalopride

  • Effective in treating severe chronic idiopathic constipation, more affordable
  • High risk of developing severe diarrhea, long term effects yet to be extensively studied

Plecanatide, predominantly used in gastrointestinal treatment, outshines alternatives due to its efficiency and reduced side effects, with notable market growth potential in the pharmaceutical sector. These Alternatives specially Linaclotide has experienced a rapid growth as detailed in our latest report.

Loading...

Research Methodology

This market research methodology defines the Plecanatide market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Plecanatide across Chronic Idiopathic Constipation and Irritable Bowel Syndrome Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Synergy Pharmaceuticals, Ironwood Pharmaceuticals, and Allergan by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Acquisition, API Production, and Dosage Form Development. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Plecanatide segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Acquisition (Pfizer Inc, Novartis AG), API Production (GlaxoSmithKline plc, Eli Lilly and Co), and Dosage Form Development. Our parallel substitute analysis examines Linaclotide, Lubiprostone, and Prucalopride, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Synergy Pharmaceuticals, Ironwood Pharmaceuticals, and Allergan, analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Plecanatide market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Plecanatide Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 506 million
Revenue Forecast in 2034USD 847 million
Growth RateCAGR of 5.9% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024478 million
Growth OpportunityUSD 370 million
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024478 million USD
Market Size 2027567 million USD
Market Size 2029636 million USD
Market Size 2030674 million USD
Market Size 2034847 million USD
Market Size 2035898 million USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredTherapeutic Application, Distribution Channel, Dosage Formulation, Prescription Mode, Patient Demographics
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledSynergy Pharmaceuticals, Ironwood Pharmaceuticals, Allergan, Valeant Pharmaceuticals, Abbott Laboratories, Novartis, AstraZeneca, Sanofi, Merck & Co., Pfizer, Takeda Pharmaceutical Company and GlaxoSmithKline
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Plecanatide Market Size, Opportunities & Strategic Insights, by Therapeutic Application

4.1Chronic Idiopathic Constipation
4.2Irritable Bowel Syndrome
Chapter 5

Plecanatide Market Size, Opportunities & Strategic Insights, by Distribution Channel

5.1Hospital Pharmacies
5.2Retail Pharmacies
5.3Online Pharmacies
Chapter 6

Plecanatide Market Size, Opportunities & Strategic Insights, by Dosage Formulation

6.1Tablets
6.2Oral Solution
Chapter 7

Plecanatide Market Size, Opportunities & Strategic Insights, by Prescription Mode

7.1OTC
7.2Prescription Based
Chapter 8

Plecanatide Market Size, Opportunities & Strategic Insights, by Patient Demographics

8.1Adults
8.2Geriatric
Chapter 9

Plecanatide Market, by Region

9.1North America Plecanatide Market Size, Opportunities, Key Trends & Strategic Insights
9.1.1U.S.
9.1.2Canada
9.2Europe Plecanatide Market Size, Opportunities, Key Trends & Strategic Insights
9.2.1Germany
9.2.2France
9.2.3UK
9.2.4Italy
9.2.5The Netherlands
9.2.6Rest of EU
9.3Asia Pacific Plecanatide Market Size, Opportunities, Key Trends & Strategic Insights
9.3.1China
9.3.2Japan
9.3.3South Korea
9.3.4India
9.3.5Australia
9.3.6Thailand
9.3.7Rest of APAC
9.4Middle East & Africa Plecanatide Market Size, Opportunities, Key Trends & Strategic Insights
9.4.1Saudi Arabia
9.4.2United Arab Emirates
9.4.3South Africa
9.4.4Rest of MEA
9.5Latin America Plecanatide Market Size, Opportunities, Key Trends & Strategic Insights
9.5.1Brazil
9.5.2Mexico
9.5.3Rest of LA
9.6CIS Plecanatide Market Size, Opportunities, Key Trends & Strategic Insights
9.6.1Russia
9.6.2Rest of CIS
Chapter 10

Competitive Landscape

10.1Competitive Dashboard & Market Share Analysis
10.2Company Profiles (Overview, Financials, Developments, SWOT)
10.2.1Synergy Pharmaceuticals
10.2.2Ironwood Pharmaceuticals
10.2.3Allergan
10.2.4Valeant Pharmaceuticals
10.2.5Abbott Laboratories
10.2.6Novartis
10.2.7AstraZeneca
10.2.8Sanofi
10.2.9Merck & Co.
10.2.10Pfizer
10.2.11Takeda Pharmaceutical Company
10.2.12GlaxoSmithKline